PDCD1 and neoplasm: Once bound, aptamers can deliver immune-modulating substances (e.g., IL-2, anti-CTLA-4, anti-PD-L1, anti-PD-1, IFN-α) directly to the tumor site, including cytokines, chemotherapeutic agents, and immune checkpoint inhibitors.